Yüklüyor......
Structural Basis of p97 Inhibition by the Site-Selective Anticancer Compound CB-5083
Inhibition of p97, a key player in the ubiquitin-proteasome degradation pathway, has been proposed as a treatment of cancer. This concept was nearly realized recently when a potent p97 inhibitor, 1-[4-(benzylamino)-5H,7H,8H-pyrano[4,3-d]pyrimidin-2-yl]-2-methyl-1H-indole-4-carboxamide (CB-5083), was...
Kaydedildi:
| Yayımlandı: | Mol Pharmacol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
The American Society for Pharmacology and Experimental Therapeutics
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6355941/ https://ncbi.nlm.nih.gov/pubmed/30591537 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.118.114256 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|